Table 5 Prevalence estimates for England with and without linked secondary care data (2014 N = 1,802,468; 2019 N = 744,496)
|  | Individuals in England eligible for secondary care data linkage in 2014 N = 1,802,468 | Individuals in England eligible for secondary care data linkage in 2019 N = 744,496 | ||||||
|---|---|---|---|---|---|---|---|---|
Standalone primary care data | Both primary and secondary care data | Standalone primary care data | Both primary and secondary care data | |||||
n | Point prevalence /100,000 (95% CI) | N | Point prevalence /100,000 (95% CI) | n | Point prevalence /100,000 (95% CI) | n | Point prevalence /100,000 (95% CI) | |
Underlying health conditions contributing to the at-risk population | ||||||||
 Chronic liver disease | 4499 | 250 (242–257) | 8104 | 450 (440–459) | 2022 | 272 (260–284) | 3941 | 529 (513–546) |
 Chronic heart disease | 87,217 | 4839 (4807–4870) | 108,711 | 6031 (5997–6066) | 29,399 | 3949 (3905–3993) | 39,083 | 5250 (5199–5300) |
 Chronic respiratory disease | 53,358 | 2960 (2936–2985) | 63,562 | 3526 (3500–3553) | 21,345 | 2867 (2829–2905) | 26,407 | 3547 (3505–3589) |
 Current asthma (only) | 125,548 | 6965 (6928–7003) | 136,702 | 7584 (7546–7623) | 48,009 | 6449 (6393–6505) | 53,030 | 7123 (7065–7182) |
 Chronic neurological disease | 60,482 | 3356 (3329–3382) | 69,932 | 3880 (3852–3908) | 21,818 | 2931 (2892–2969) | 26,284 | 3530 (3489–3573) |
 Diabetes mellitus | 110,144 | 6111 (6076–6146) | 114,149 | 6333 (6297–6369) | 48,461 | 6509 (6453–6566) | 50,760 | 6818 (6761–6876) |
 Organ transplant recipient | 1470 | 82 (77–86) | 1732 | 96 (92–101) | 707 | 95 (88–102) | 838 | 113 (105–120) |
 Asplenia/sickle cell disease | 2545 | 141 (136–147) | 2878 | 160 (154–166) | 1089 | 146 (138–155) | 1346 | 181 (171–191) |
 Other immunosuppression | 14,134 | 784 (771–797) | 32,537 | 1805 (1786–1825) | 5035 | 676 (658–695) | 7663 | 1029 (1006–1052) |
 Chronic kidney disease | 159,241 | 8835 (8793–8876) | 159,379 | 8842 (8801–8884) | 54,661 | 7342 (7283–7401) | 54,774 | 7357 (7298–7417) |
 Severe obesity (BMI ≥40 kg/m2) | 36,668 | 2581 (2555–2607) | 36,668 | 2581 (2555–2607) | 16,706 | 2898 (2855–2942) | 16,706 | 2898 (2855–2942) |
At-risk populationa | ||||||||
 At-risk populationa | 450,601 | 24,999 (24,936–25,062) | 483,071 | 26,801 (26,736–26,865) | 175,420 | 23,562 (23,466–23,659) | 188,716 | 25,348 (25,249–25,447) |
 among those aged < 70 years | 276,158 | 17,756 (17,696–17,816) | 303,528 | 19,516 (19,453–19,578) | 112,168 | 17,286 (17,194–17,378) | 123,038 | 18,961 (18,866–19,057) |
 among those aged ≥70 years | 174,443 | 70,579 (70,399–70,759) | 179,543 | 72,643 (72,466–72,818) | 63,252 | 66,157 (65,856–66,457) | 65,678 | 68,694 (68,399–68,988) |
 Multimorbidity | 133,803 | 7423 (7385–7462) | 155,802 | 8644 (8603–8685) | 48,009 | 6449 (6393–6505) | 56,827 | 7633 (7573–7693) |
Cancer survivors | ||||||||
 Incident cancer in previous year | 8343 | 463 (453–473) | 10,680 | 593 (581–604) | 2936 | 394 (380–409) | 3806 | 511 (495–528) |
 Incident cancer in previous 5 years | 31,195 | 1731 (1712–1750) | 36,815 | 2042 (2022–2063) | 11,708 | 1573 (1544–1601) | 13,854 | 1861 (1830–1892) |